Iron deficiency and von Willebrand disease: the relationship and interdisciplinary approach. A review and own data
- Authors: Vinogradova M.А.1
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 27, No 3 (2025)
- Pages: 183-189
- Section: REVIEW
- URL: https://journals.rcsi.science/2079-5831/article/view/316012
- DOI: https://doi.org/10.26442/20795696.2025.3.203410
- ID: 316012
Cite item
Full Text
Abstract
Iron deficiency conditions are common for clinical practice especially in women of reproductive age. In coagulopathies, chronic blood loss, in particular heavy menstrual bleeding, becomes the main cause of iron deficiency anemia. The most common form of coagulopathy is von Willebrand disease, and if its severe forms are established in childhood, then mild ones can proceed latent for a long time. Iron deficiency not only worsens the quality of life but can also complicate the course of the underlying disease, creating a vicious circle. Management of such patients is a clinical challenge and requires a comprehensive interdisciplinary approach: timely diagnosis, assessment of the volume of blood loss, its correction, selection of the optimal scheme for replenishing iron deficiency and mandatory elimination of the main hemostasis disorder. This article discusses modern principles of diagnosis and therapy of iron deficiency in women with coagulopathies. The patient model for a preventive approach is presented. The basis of therapy in case of persistent excessive blood loss are iron preparations for parenteral administration, in particular, ferric carboxymaltose. The timely administration of adequate doses of a well-tolerated iron preparation, which became possible with the advent of ferric carboxymaltose, makes it possible to prevent severe forms of anemia and improve the patients’ quality of life.
Full Text
##article.viewOnOriginalSite##About the authors
M. А. Vinogradova
Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: mary-grape@ya.ru
ORCID iD: 0000-0001-9827-1922
Cand. Sci. (Med.)
Russian Federation, MoscowReferences
- Доброхотова Ю.Э., Кузнецова О.В. Железодефицитная анемия в акушерско-гинекологической практике. Акушерство и гинекология. 2016;8:10-5 [Dobrokhotova YuE, Kuznetsova OV. Iron deficiency anemia in obstetric and gynecological practice. Akusherstvo i Ginekologiia. 2016;8:10-5 (in Russian)]. doi: 10.18565/aig.2016.8.10-15
- Myrin-Westesson L, Elfvinge P, Zetterberg E, Olsson A. Prevalence of heavy menstrual bleeding, iron deficiency, iron deficiency anemia, and treatment in women with von Willebrand disease: a cohort study. Res Pract Thromb Haemost. 2025;9(4):102949. doi: 10.1016/j.rpth.2025.102949
- Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease – 2023 executive summary. Blood Adv. 2021;5(1):301-25. doi: 10.1182/bloodadvances.2020003264
- American College of Obstetricians and Gynecologists. Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding. Committee Opinion No. 785. Obstet Gynecol. 2019;134(3):e71-83. doi: 10.1097/AOG.0000000000003411
- Lavin M, Aguila S, Dalton N, et al. Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Advances. 2018;2(14):1784-91. doi: 10.1182/bloodadvances.2018017418
- MacLean B, Sholzberg M, Weyand AC, et al. Identification of women and girls with iron deficiency in the reproductive years. Int J Gynecol Obstet. 2023;162(Suppl. 2):58-67. doi: 10.1002/ijgo.14948
- Snook J, Bhala N, Beales I, et al. BSG guideline for management of iron deficiency anemia in adults. Gut. 2021;70(11):2030-51. doi: 10.1136/gutjnl-2021-325210
- Зырянов С.К., Байбулатова Е.А. Выбор препарата железа для парентерального введения при железодефицитной анемии (обзор). Терапевтический архив. 2024;96(4):407-18 [Zyryanov SK, Baybulatova EA. Selection of parenteral iron supplement for iron deficiency anemia: A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(4):407-18 (in Russian)]. doi: 10.26442/00403660.2024.04.202693
- Turan O, Gomez K, Kadir RA. Review of interventions and effectiveness for heavy menstrual bleeding in women with moderate and severe von Willebrand disease. Haemophilia. 2024;30:1177-84. doi: 10.1111/hae.15078
- Зозуля Н.И., Яструбинецкая О.И. Проблемы комплаентности пациентов с болезнью Виллебранда. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2022;21(1):83-7 [Zozulya NI, Yastrubinetskaya OI. Compliance with therapy in patients with von Willebrand's disease. Voprosy Gematologii/Onkologii i Immunopatologii v Pediatrii. 2022;21(1):83-7 (in Russian)]. doi: 10.24287/1726-1708-2022-21-1-83-87
- Munro MG, Mast AE, Powers JM, et al. The relationship between heavy menstrual bleeding, iron deficiency and iron-deficiency anemia. Am J Obstet Gynecol. 2023;229(1):1-9. doi: 10.1016/j.ajog.2023.01.017
- Zoller H, Schaefer B, Blumenstein I, et al. Hypophosphataemia after ferric carboxymaltose vs ferric derisomaltose (PHOSPHARE-IBD): randomized trial. Gut. 2023;72(4):644-53. doi: 10.1136/gutjnl-2022-327897
- Injectafer® (Ferric Carboxymaltose). Prescribing Information. U.S. FDA label (2021–2024 updates).
- Ferinject® (Ferric Carboxymaltose). Product Monograph. CSL Behring; 2024.
- Виноградова М.А. Карбоксимальтозат железа в лечении анемии в акушерско-гинекологической практике. Клиническая фармакология и терапия. 2014;23(4):1-5 [Vinogradova MA. Ferric carboxymaltose in gynaecological practice. Clin Pharmacol Ther. 2014;23(4):1-5 (in Russian)].
- Akpan IJ, Narang M, Zampaglione E, et al. Iron deficiency anemia in patients with heavy menstrual bleeding: The patients’ perspective from diagnosis to treatment. Women’s Health (Lond). 2025;21:17455057251321221. doi: 10.1177/17455057251321221
- Secilmis S, Iskender D, Candir BA, et al. Efficiency of intravenous iron carboxymaltose in patients with iron-deficiency anemia due to heavy menstrual bleeding: a single-center experience. Eur Rev Med Pharmacol Sci. 2022;26(10):3487-92. doi: 10.26355/eurrev_202205_28843
- Драпкина О.М., Авалуева Е.Б., Бакулин И.Г., и др. Ведение пациентов с железодефицитной анемией на этапе оказания первичной медико-санитарной помощи. Практическое руководство. М.: Видокс, 2021. [Drapkina OM, Avalueva EB, Bakulin IG, et al. Vedenie patsientov s zhelezodefitsitnoi anemiei na etape okazaniia pervichnoi mediko-sanitarnoi pomoshchi. Prakticheskoe rukovodstvo. Moscow: Vidoks, 2021 (in Russian)].
- Zia A, Stanek J, Christian-Rancy M, et al. Iron deficiency and fatigue among adolescents with bleeding disorders. Am J Hematol. 2022;97(1):60-7. doi: 10.1002/ajh.2638
- VanderMeulen H, Arya S, Nersesian S, et al. What have we learned about the patient’s experience of von Willebrand disease? A focus on women. Hematology Am Soc Hematol Educ Program. 2022;2022(1):631-6. doi: 10.1182/hematology.2022000391
- Ragni MV, Rothenberger SD, Feldman R, et al. Recombinant von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in VWD: Randomized Crossover Trial. Lancet Haematol. 2023;10(8):e612-23. doi: 10.1016/S2352-3026(23)00119-9
- Kiss C, Boda Z, Khayat CD, et al. Eficacy of regular prophylaxis with a plasma-derived von Willebrand factor/factor VIIIconcentrate with a 1:1 activity ratio in reducing heavy menstrual bleeding in girls/women with von Willebrand disease. AJOG Glob Rep. 2025;5(2):100501.
- VanderMeulen H, Tang GH, Sholzberg M. Tranexamic acid for management of heavy vaginal bleeding: barriers to access and myths surrounding its use. Res Pract Thromb Haemost. 2024;8(3):e102389 doi: 10.1016/j.rpth.2024.102389
- Committee on Adolescent Health Care; Committee on Gynecologic Practice. Committee Opinion No. 580: Von Willebrand disease in women. Obstet Gynecol. 2013;122:1368-73. doi: 10.1097/01.AOG.0000438961.38979.19
- Winikoff R, Scully MF, Robinson KS. Women and inherited bleeding disorders – A review with a focus on key challenges for 2019. Transfus Apher Sci. 2019;58(5):613-22. doi: 10.1016/j.transci.2019.08.013
- NICE National Institute for Health and Care Excellence. Heavy Menstrual Bleeding: Assessment and Management. Guideline 88. National Institute for Health and Care Excellence; 2021. Available at: https://www.nice.org.uk/guidance/ng88/resources/heavy-menstrual-bleeding-assessment-and-management-pdf-1837701412549. Accessed: 5 Sept 2022.
Supplementary files
